Prime Studies Show High Costs Among Asthma, HAE Biologics
Prime Therapeutics LLC recently released the results of two studies focused on two classes of high-cost biologics, asthma and hereditary angioedema (HAE). Both conditions have seen new therapies recently and may be candidates for value-based contracts.
While more than 25 million people in the United States suffer from asthma, about 5% to 10% of those suffer from severe allergic or eosinophilic asthma. While asthma overall has a societal cost of around $56 billion, those patients account for almost 50% of that cost. Global Initiative for Asthma 2019 guidelines recommend an asthma biologic for this subset of patients, and the first Prime study examined the use of five biologics: Cinqair (reslizumab), Dupixent (dupilumab), Fasenra (benralizumab), Nucala (mepolizumab) and Xolair (omalizumab).
Related Posts

More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
READ MORE
New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati
READ MORE